好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

2026 Annual Meeting | C191 - Multiple Sclerosis Disease-modifying Treatment

Wednesday 04/22/26
03:30 PM - 05:30 PM CDT Add To Calendar
This program will be presented both in-person and online
This program will be available in the meeting's On Demand product.
Seminar
Veronica P. Cipriani, MD
Multiple Sclerosis
2.00 CME credits
Brain Health
Event Timeline
No timeline events available at this time.
Faculty Disclosures
Veronica P. Cipriani, MD Dr. Cipriani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. Dr. Cipriani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Cipriani has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for TG Pharmaceuticals. Dr. Cipriani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi Genzyme. Dr. Cipriani has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Cipriani has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. Dr. Cipriani has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Genentech. Dr. Cipriani has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for TG Therapeutics. Dr. Cipriani has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sanofi. Dr. Cipriani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant with Vaccine Injury Compensation Program. Dr. Cipriani has received personal compensation in the range of $500-$4,999 for serving as a Member of Board of Directors with Chicago MS Alliance.